Objective To develop a new evidence‐based, pharmacologic treatment guideline for
rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the …

Hepatitis B reactivation associated with immune-suppressive and biological therapies is
emerging to be an important cause of morbidity and mortality in patients with current or prior …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

Hepatitis B virus (HBV) infection causes chronic hepatitis and has long term complications.
Individuals ever infected with HBV are at risk of viral reactivation under certain …

This article has an accompanying continuing medical education activity on page e16.
Learning Objective: Upon completion of the CME activity, successful learners will be able to …

Despite the availability of several new systemic agents for psoriasis treatment, choosing the
right therapy in certain patient populations can be challenging. There are few up-to-date …

Hepatitis B flare, defined as an event with abrupt rise of alanine aminotransferase (ALT)
levels to> 5 times the upper limit of normal during chronic hepatitis B virus (HBV) infection, is …

Diseases (AASLD) also presented and continued to revise their clinical practice guidelines,
and the latest updates were in 2015, 2017, and 2018. However, since the medical …

Aim To update recommendations based on current best evidence concerning the treatment
of rheumatoid arthritis (RA), focusing particularly on the role of targeted therapies, to inform …

Christopher R. Holroyd1, Rakhi Seth1, Marwan Bukhari2, Anshuman Malaviya3, Claire
Holmes1, Elizabeth Curtis4, Christopher Chan1, Mohammed A. Yusuf3, Anna Litwic4, 5 …